Ask AI
ProCE Banner Activity

ACHILES: Randomized Phase II Study of Atezolizumab vs Observation After Chemoradiotherapy for Limited-Stage SCLC

Conference Coverage
Slideset

In the randomized phase II ACHILES trial, although well tolerated, treatment with atezolizumab vs observation in patients with LS SCLC with CR/PR/SD following CRT did not significantly improve progression-free or overall survival.

Released: June 06, 2025

Expiration: December 05, 2025

Share

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by educational grants from AstraZeneca, Boehringer Ingelheim Pharmaceuticals, Inc., Daiichi Sankyo, Inc, Genentech, a member of the Roche Group, and PharmaMar.

AstraZeneca

Boehringer Ingelheim Pharmaceuticals, Inc.

Daiichi Sankyo, Inc.

Genentech, a member of the Roche Group

PharmaMar